HLK-0001

HLK-0001 is a drug candidate being developed by Shenzhen Pharmacin, primarily for the treatment of psoriasis. It is part of the company's pipeline of reformulated drug products developed through the 505(b)(2) regulatory pathway, which aims to improve patient outcomes by enhancing bioavailability, safety, and compliance of existing medications. The drug is currently in early-phase development, with indications listed in company materials as psoriasis and a condition abbreviated as 'NDC'. While the specific active ingredient and mechanism of action for HLK-0001 have not been publicly disclosed, it likely utilizes Pharmacin's proprietary formulation technologies, such as SpraySol™, to optimize delivery for dermatological or other systemic applications.

Other names

clobetasol propionate sprayclobetasol propionate topical solution